Genenta Science (NASDAQ:GNTA)'s Pierluigi Paracchi joins Proactive to talk about its clinical-stage biotechnology company.
The Nasdaq-listed firm is pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumour cancers.
He says they have enough cash in the bank to be able to treat patients in its phase II trial which will take place in 2023.